Life-Threatening Bleeding

Get the facts.

Patients At Risk
  • ~408 patients each day are expected to be hospitalized with an apixaban- or rivaroxaban- related bleed in 20181
  • ~70 patients die each day following hospitalization from apixaban- or rivaroxaban- related bleeds1-3
Intracranial Hemorrhage (ICH)
  • Substantial hematoma expansion (volume increase of ≥33% or ≥6 mL) occurred in approximately 40% of ICH patients taking NOACs4
  • 44% of intracerebral hemorrhage patients on apixaban or rivaroxaban experience a substantial hematoma expansion within 6 hours of presentation5
  • In non-valvular atrial fibrillation clinical trials, 48% of rivaroxaban patients (Rocket AF Trial) and 45% of apixaban patients (Aristotle Trial) with ICH died within 30 days3,6
Gastrointestinal Bleed
  • Results from randomized controlled trials show that gastrointestinal bleeds account for 39%-56% of all major bleeds in rivaroxaban- or apixaban-treated patients7,8

Andexxa is for patients taking rivaroxaban or apixaban who are experiencing life- threatening or uncontrolled bleeding, due to

  • Intracranial Hemorrhage
    •  Intracerebral, subdural, subarachnoid
  •  Bleeding at a Critical Site
    •  Intraocular, pericardial, intraspinal, intrarticular
  •  Major Bleed with Hemodynamic Instability
    •  Including, but not limited to: gastrointestinal, retroperitoneal, genitourinary tract
  •  Major Trauma
    •  Blunt or penetrating injury